**Author reply**

Dear Sir,

I appreciate comments from the authors.[1] I am glad that article on ziv-aflibercept has attracted attention from readers for Indian Journal of Ophthalmology. I agree with the authors that we do not have long-term data on ziv-aflibercept; therefore, I reported short-term safety results. After observing no clinical side effects in injected eye on the 5th day, I injected in the other eye. The patient was stable during the treatment-free interval with visual acuity of 20/100 before the recurrent attack. The response to ziv-aflibercept was better than bevacizumab. Therefore, ziv-aflibercept was considered as the treatment of choice at 1-month follow-up as well. The patient is under regular treatment until now. Therefore, I am unable to comment upon whether ziv-aflibercept prolonged the treatment-free interval or not.
Again, I appreciate authors’ interest in this article.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

Reference

1. Sen A, Mitra A, Malhotra PP, Gupta S. Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion. Indian J Ophthalmol 2015;63:751.

Jay Chhablani

Smt. Kanuri Santhamma Retina Vitreous Centre, L. V. Prasad Eye Institute, Hyderabad, Telangana, India

Correspondence to: Dr. Jay Chhablani,
Smt. Kanuri Santhamma Retina Vitreous Centre,
L.V. Prasad Eye Institute, Kallam Anji Reddy Campus,
L. V. Prasad Marg, Banjara Hills, Hyderabad - 500 034,

Telangana, India.
E-mail: jay.chhablani@gmail.com

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.